| 2021-06-09 | +211.9% | news | markets.businessinsider.com | Aethlon Medical Stock Explodes 465% Amid Chatter About COVID-19 Treatment - markets.businessinsider.com |
| 2025-08-20 | +94.5% | news | Seeking Alpha | Aethlon Medical files to sell common stock, warrants, no amount given |
| 2025-09-03 | -56.9% | news | Investorideas.com | Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Announces Issuance of Hemopurifier Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC) - Investorideas.com |
| 2025-09-04 | -47.2% | news | Seeking Alpha | Aethlon Medical prices $4.5M public offering with 5-Year warrants; shares down 47% |
| 2025-09-04 | -47.2% | news | Investorideas.com | Medtech Stocks — How a a company's IP portfolio Creates Market Leaders - Investorideas.com |
| 2025-08-21 | +42.1% | news | TipRanks | Why Is Aethlon Medical Stock (AEMD) Up 60% Today? - TipRanks |
| 2025-08-21 | +42.1% | news | StocksToTrade | Aethlon Medical’s Stock Surge Raises Eyebrows - StocksToTrade |
| 2025-06-27 | -39.1% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-06-06 | +34.2% | news | InvestorPlace | Why Is Aethlon Medical (AEMD) Stock Up 82% Today? - InvestorPlace |
| 2023-07-06 | +30.4% | legal | SEC EDGAR | AEMD 8-K: 5.02 (SEC Filing) |
| 2022-06-28 | +27.6% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2024-12-20 | +26.4% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2023-04-25 | -24.4% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2023-01-30 | +23.2% | news | InvestorPlace | Why Is Aethlon Medical (AEMD) Stock Up 50% Today? - InvestorPlace |
| 2025-10-16 | -22.7% | news | Investing.com | Aethlon Medical enacts 1-for-10 reverse stock split effective Thursday - Investing.com |
| 2025-06-26 | -21.7% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript |
| 2025-06-26 | -21.7% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$8.58 misses by $2.76 |
| 2025-06-26 | -21.7% | legal | Stock Titan | AEMD SEC Filings - Aethlon Medical 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-03-13 | +21.5% | M&A | NewMediaWire | Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives |
| 2026-03-13 | +21.5% | news | GlobeNewswire | Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing |
| 2026-03-13 | +21.5% | news | Investorideas.com | Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) on the Move – Morning High of $2.09 - Investorideas.com |
| 2023-10-04 | -21.1% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2024-08-13 | +20.6% | earnings | Seeking Alpha | Aethlon Medical Q1 2025 Earnings Preview |
| 2026-03-12 | +20.3% | news | PR Newswire | Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities |
| 2026-03-12 | +20.3% | news | Investorideas.com | Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Gains on News - Investorideas.com |
| 2025-06-25 | +18.9% | earnings | Seeking Alpha | Aethlon Medical FY 2025 Earnings Preview |
| 2025-01-29 | +17.7% | news | Investorideas.com | Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update - Investorideas.com |
| 2021-06-11 | -16.5% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2024-05-10 | -16.2% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2024-05-11 | -16.1% | earnings | MarketBeat | Aethlon Medical (AEMD) Stock Forecast and Price Target 2026 - MarketBeat |
| 2026-01-26 | -15.5% | legal | SEC EDGAR | AEMD 8-K: 1.01 and (SEC Filing) |
| 2026-01-26 | -15.5% | news | Investing.com | Aethlon Medical amends warrant terms to allow immediate exercise - Investing.com |
| 2024-06-27 | -15.0% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript |
| 2024-06-27 | -15.0% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2024-04-25 | -11.7% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2025-06-05 | -11.3% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2025-06-05 | -11.3% | news | Investing.com | aethlon medical announces reverse stock split effective june 6 - Investing.com |
| 2025-11-12 | +10.8% | analyst | Seeking Alpha | Aethlon Medical signals expanded Australian oncology enrollment strategy while operating loss narrows to $1.5M |
| 2025-11-12 | +10.8% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript |
| 2025-11-12 | +10.8% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$3.74 misses by $0.08 |
| 2025-11-12 | +10.8% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-09-19 | -10.7% | legal | SEC EDGAR | AEMD 8-K: 5.02, 5.03, 5.07, 8.01 (SEC Filing) |
| 2022-12-20 | +9.9% | news | GuruFocus | Lee D Arnold Net Worth (2026) - GuruFocus |
| 2025-02-13 | -8.5% | news | Seeking Alpha | Aethlon Medical strengthens oncology trial with protocol updates and cost reductions |
| 2025-02-13 | -8.5% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript |
| 2026-02-11 | -8.4% | earnings | Seeking Alpha | Aethlon Medical Q3 2026 Earnings Preview |
| 2024-08-12 | +8.3% | legal | Seeking Alpha | Aethlon Medical receives second ethics committee approval for Hemopurifier cancer trial |
| 2024-08-12 | +8.3% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2025-09-12 | -8.1% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2025-02-12 | -8.1% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$0.13 beats by $0.07 |
| 2025-02-12 | -8.1% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-11-14 | -8.0% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2022-08-09 | -7.9% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2021-08-09 | -7.7% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2025-08-13 | -7.5% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$0.85 beats by $0.01 |
| 2025-08-13 | -7.5% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-17 | +7.3% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2026-03-17 | +7.3% | news | TipRanks | Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity - TipRanks |
| 2024-05-17 | +7.2% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2025-08-14 | -7.1% | news | Seeking Alpha | Aethlon Medical signals Australia oncology trial completion by early 2026 while scaling back India plans |
| 2025-08-14 | -7.1% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call Transcript |
| 2025-07-15 | +7.1% | news | Investorideas.com | Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Reports Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort - Investorideas.com |
| 2026-02-13 | +6.8% | news | Seeking Alpha | Aethlon Medical signals faster clinical trial enrollment amid Hemopurifier advancements |
| 2026-02-13 | +6.8% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript |
| 2024-02-14 | -6.8% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2026-02-04 | -6.4% | earnings | Stock Titan | Aethlon Medical sets Feb. 12 call on fiscal Q3 results - Stock Titan |
| 2022-11-08 | -6.3% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Aethlon Medical (AEMD) - Zacks Investment Research |
| 2022-09-13 | -6.3% | analyst | TradingView | AEMD Forecast — Price Target — Prediction for 2027 - TradingView |
| 2021-11-09 | -6.2% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2021-06-24 | -6.1% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | -6.1% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2022-03-24 | -5.9% | legal | SEC EDGAR | AEMD 8-K: 1.01 and (SEC Filing) |
| 2022-09-29 | -5.8% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2022-09-29 | -5.8% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2025-03-17 | +5.7% | legal | SEC EDGAR | AEMD 8-K: 1.01, 3.02, 3.03 (SEC Filing) |
| 2023-11-14 | +5.7% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2023-11-13 | -5.3% | legal | SEC EDGAR | AEMD 8-K: 5.02 (SEC Filing) |
| 2025-12-08 | -5.3% | legal | SEC EDGAR | AEMD 8-K: 1.01, 3.03, 7.01 (SEC Filing) |
| 2024-08-14 | -5.1% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript |
| 2024-08-14 | -5.1% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$0.34 misses by $0.02 |
| 2024-08-14 | -5.1% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-08-14 | -5.1% | earnings | InvestorPlace | AEMD Stock Earnings: Aethlon Medical Misses EPS for Q1 2025 - InvestorPlace |
| 2026-03-10 | -4.9% | news | GlobeNewswire | Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th |
| 2026-04-22 | -4.9% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | AEMD (Aethlon Medical Inc.) posts narrow Q1 2026 EPS beat, shares tick higher on modest positive investor sentiment. - Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-02-12 | -4.7% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$2.45 misses by $0.03 |
| 2026-02-12 | -4.7% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-21 | -4.5% | news | Stock Titan | Aethlon Medical (AEMD) director receives 21,815-share RSU stock grant - Stock Titan |
| 2026-04-21 | -4.5% | news | Stock Titan | Director at Aethlon Medical (AEMD) receives 21,815-share RSU grant - Stock Titan |
| 2026-04-21 | -4.5% | news | Stock Titan | Aethlon Medical (AEMD) director receives 21,815-share RSU award at $2.29 - Stock Titan |
| 2026-04-21 | -4.5% | news | Stock Titan | Director Chetan Shah receives 21,815 RSUs at Aethlon Medical (AEMD) - Stock Titan |
| 2021-11-01 | -4.5% | legal | SEC EDGAR | AEMD 8-K: 1.01 (SEC Filing) |
| 2024-11-12 | -4.4% | earnings | Seeking Alpha | Aethlon Medical Q2 2025 Earnings Preview |
| 2024-11-12 | -4.4% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2026-02-19 | -4.3% | analyst | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript |
| 2026-04-13 | +4.2% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Can Aethlon (AEMD) Stock Beat Estimates | Price at $2.16, Down 0.46% - Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-01 | -4.0% | news | Stock Titan | Director at Aethlon (NASDAQ: AEMD) forfeits shares to cover taxes - Stock Titan |
| 2026-04-01 | -4.0% | news | Stock Titan | Aethlon Medical (NASDAQ: AEMD) director forfeits 178 shares for tax withholding - Stock Titan |
| 2026-04-01 | -4.0% | news | Stock Titan | Aethlon Medical (AEMD) director forfeits 178 shares to cover RSU taxes - Stock Titan |
| 2021-07-01 | -4.0% | legal | SEC EDGAR | AEMD 8-K: 5.02 (SEC Filing) |
| 2025-11-11 | -3.7% | earnings | Seeking Alpha | Aethlon Medical Q2 2026 Earnings Preview |
| 2025-09-09 | -3.5% | legal | SEC EDGAR | AEMD 8-K: 1.01, 8.01 (SEC Filing) |
| 2024-11-13 | +3.2% | earnings | Seeking Alpha | Aethlon Medical GAAP EPS of -$0.20 in-line |
| 2024-11-13 | +3.2% | legal | SEC EDGAR | AEMD 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-02-13 | -3.0% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2022-03-28 | -2.6% | legal | SEC EDGAR | AEMD 8-K: 5.02 (SEC Filing) |
| 2024-03-26 | -2.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-08-12 | -2.2% | earnings | Seeking Alpha | Aethlon Medical Q1 2026 Earnings Preview |
| 2023-06-28 | +2.1% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2024-10-02 | -2.1% | legal | SEC EDGAR | AEMD 8-K: 5.02, 5.07 (SEC Filing) |
| 2023-12-22 | +2.0% | legal | SEC EDGAR | AEMD 8-K: 5.02 and (SEC Filing) |
| 2026-04-06 | -1.9% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Is Aethlon (AEMD) Stock Undervalued Now | Price at $2.17, Up 2.36% - Elite Alerts - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2023-11-27 | +1.9% | legal | SEC EDGAR | AEMD 8-K: 5.02 and (SEC Filing) |
| 2024-05-24 | +1.7% | legal | SEC EDGAR | AEMD 8-K: 8.01 (SEC Filing) |
| 2024-10-03 | +1.6% | legal | SEC EDGAR | AEMD 8-K: 5.02 (SEC Filing) |
| 2026-04-20 | +1.3% | news | Cổng thông tin điện tử tỉnh Lào Cai | Aethlon (AEMD) Stock Strangle (Smart Money Active) 2026-04-20 - Community Volume Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2022-02-14 | -1.3% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |
| 2025-02-11 | -1.2% | earnings | Seeking Alpha | Aethlon Medical Q3 2025 Earnings Preview |
| 2024-09-19 | -1.2% | legal | SEC EDGAR | AEMD 8-K: 8.01 and (SEC Filing) |
| 2026-03-18 | +1.2% | executive | Zacks Small Cap Research | OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCR |
| 2026-03-18 | +1.2% | executive | Zacks Small Cap Research | AEMD: Positive Takeaways From CEO Chat |
| 2025-10-08 | +1.1% | news | TMX Newsfile | Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates - TMX Newsfile |
| 2026-02-24 | +0.9% | news | GlobeNewswire | Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream |
| 2026-03-24 | +0.6% | news | Zacks Small Cap Research | AEMD: Hitting Key Milestones as Company Advances Clinical Study |
| 2026-03-24 | +0.6% | news | PR Newswire | Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review |
| 2026-03-24 | +0.6% | news | Investorideas.com | Novel Immunotherapeutics Stocks in the News (Nasdaq:AEMD), (Nasdaq:HURA) (NYSE: AZN) (Nasdaq: ELTX) - Investorideas.com |
| 2024-11-14 | -0.5% | earnings | Seeking Alpha | Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript |
| 2026-03-06 | +0.4% | news | GlobeNewswire | Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th |
| 2026-02-23 | +0.3% | legal | SEC EDGAR | AEMD 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2026-02-23 | +0.3% | executive | Stock Titan | Ask Aethlon Medical’s CEO and CFO live at Emerging Growth Conference - Stock Titan |
| 2023-08-10 | +0.0% | legal | SEC EDGAR | AEMD 8-K: 2.02 and (SEC Filing) |